Literature DB >> 22993539

EML4-ALK fusion transcripts in immunohistochemically ALK-positive non-small cell lung carcinomas.

Kazuya Shinmura1, Shinji Kageyama, Hisaki Igarashi, Takaharu Kamo, Takahiro Mochizuki, Kazuya Suzuki, Masayuki Tanahashi, Hiroshi Niwa, Hiroshi Ogawa, Haruhiko Sugimura.   

Abstract

EML4-ALK fusion transcripts have been found in a subset of non-small cell lung carcinomas (NSCLCs); however, their protein expression status has not yet been fully elucidated. In this study we investigated ALK protein expression in 302 NSCLCs and 291 gastric carcinomas by means of immunohistochemical analysis. Twelve (4.0%) NSCLCs, but none of the gastric carcinomas, were found to be positive for ALK. The ALK signal was detected in the cytoplasm of cancer cells. Subsequent RNA analysis of 10 RNA-available, immunohistochemically ALK-positive tumors revealed that three tumors had EML4-ALK variant 1, three tumors had variant 2, three tumors had variants 3a and 3b, and one tumor had a novel variant in which exon 14 of EML4 is connected to the nucleotide at position 53 of exon 20 of ALK by a 2-bp insertion. These results suggest that immunohistochemical ALK detection is a useful way to screen NSCLCs for tumors containing ALK fusions.

Entities:  

Year:  2010        PMID: 22993539      PMCID: PMC3445876          DOI: 10.3892/etm_00000042

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  23 in total

1.  Chromosomal imbalances, 11q21 rearrangement and MECT1-MAML2 fusion transcript in mucoepidermoid carcinomas of the salivary gland.

Authors:  Irmgard Verdorfer; Andre Fehr; Jörn Bullerdiek; Nina Scholz; Andrea Brunner; Jens Krugmann; Martina Hager; Heike Haufe; Gregor Mikuz; Arne Scholtz
Journal:  Oncol Rep       Date:  2009-08       Impact factor: 3.906

Review 2.  Oncogenic transcription factors in the human acute leukemias.

Authors:  A T Look
Journal:  Science       Date:  1997-11-07       Impact factor: 47.728

3.  Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.

Authors:  Ultan McDermott; A John Iafrate; Nathanael S Gray; Toshi Shioda; Marie Classon; Shyamala Maheswaran; Wenjun Zhou; Hwan Geun Choi; Shannon L Smith; Lori Dowell; Lindsey E Ulkus; Georgiana Kuhlmann; Patricia Greninger; James G Christensen; Daniel A Haber; Jeffrey Settleman
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

4.  Induction of centrosome amplification and chromosome instability in p53-deficient lung cancer cells exposed to benzo[a]pyrene diol epoxide (B[a]PDE).

Authors:  K Shinmura; M Iwaizumi; H Igarashi; K Nagura; H Yamada; M Suzuki; K Fukasawa; H Sugimura
Journal:  J Pathol       Date:  2008-11       Impact factor: 7.996

5.  Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.

Authors:  Kengo Takeuchi; Young Lim Choi; Manabu Soda; Kentaro Inamura; Yuki Togashi; Satoko Hatano; Munehiro Enomoto; Shuji Takada; Yoshihiro Yamashita; Yukitoshi Satoh; Sakae Okumura; Ken Nakagawa; Yuichi Ishikawa; Hiroyuki Mano
Journal:  Clin Cancer Res       Date:  2008-10-15       Impact factor: 12.531

Review 6.  Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer.

Authors:  Hiroyuki Mano
Journal:  Cancer Sci       Date:  2008-11-20       Impact factor: 6.716

7.  A mouse model for EML4-ALK-positive lung cancer.

Authors:  Manabu Soda; Shuji Takada; Kengo Takeuchi; Young Lim Choi; Munehiro Enomoto; Toshihide Ueno; Hidenori Haruta; Toru Hamada; Yoshihiro Yamashita; Yuichi Ishikawa; Yukihiko Sugiyama; Hiroyuki Mano
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-08       Impact factor: 11.205

8.  Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

Authors:  Klarisa Rikova; Ailan Guo; Qingfu Zeng; Anthony Possemato; Jian Yu; Herbert Haack; Julie Nardone; Kimberly Lee; Cynthia Reeves; Yu Li; Yerong Hu; Zhiping Tan; Matthew Stokes; Laura Sullivan; Jeffrey Mitchell; Randy Wetzel; Joan Macneill; Jian Min Ren; Jin Yuan; Corey E Bakalarski; Judit Villen; Jon M Kornhauser; Bradley Smith; Daiqiang Li; Xinmin Zhou; Steven P Gygi; Ting-Lei Gu; Roberto D Polakiewicz; John Rush; Michael J Comb
Journal:  Cell       Date:  2007-12-14       Impact factor: 41.582

9.  DNA vaccination against bcr-abl-positive cells in mice.

Authors:  Vincent Lucansky; Eva Sobotkova; Ruth Tachezy; Martina Duskova; Vladimir Vonka
Journal:  Int J Oncol       Date:  2009-10       Impact factor: 5.650

10.  EML4-ALK fusion transcript is not found in gastrointestinal and breast cancers.

Authors:  Y Fukuyoshi; H Inoue; Y Kita; T Utsunomiya; T Ishida; M Mori
Journal:  Br J Cancer       Date:  2008-04-15       Impact factor: 7.640

View more
  4 in total

1.  RSPO fusion transcripts in colorectal cancer in Japanese population.

Authors:  Kazuya Shinmura; Tomoaki Kahyo; Hisami Kato; Hisaki Igarashi; Shun Matsuura; Satoki Nakamura; Kiyotaka Kurachi; Toshio Nakamura; Hiroshi Ogawa; Kazuhito Funai; Masayuki Tanahashi; Hiroshi Niwa; Haruhiko Sugimura
Journal:  Mol Biol Rep       Date:  2014-05-22       Impact factor: 2.316

2.  Identification of 5 novel germline APC mutations and characterization of clinical phenotypes in Japanese patients with classical and attenuated familial adenomatous polyposis.

Authors:  Hong Tao; Kazuya Shinmura; Hidetaka Yamada; Masato Maekawa; Satoshi Osawa; Yasuhiro Takayanagi; Kazuya Okamoto; Tomohiro Terai; Hiroki Mori; Toshio Nakamura; Haruhiko Sugimura
Journal:  BMC Res Notes       Date:  2010-11-16

3.  Detection of EML4-ALK in lung adenocarcinoma using pleural effusion with FISH, IHC, and RT-PCR methods.

Authors:  Leilei Liu; Ping Zhan; Xiaodie Zhou; Yong Song; Xiaojun Zhou; Like Yu; Jiandong Wang
Journal:  PLoS One       Date:  2015-03-18       Impact factor: 3.240

4.  Non-small cell lung cancer with EML4-ALK translocation in Chinese male never-smokers is characterized with early-onset.

Authors:  Yongjun Guo; Jie Ma; Xiaodong Lyu; Hai Liu; Bing Wei; Jiuzhou Zhao; Shuang Fu; Lu Ding; Jihong Zhang
Journal:  BMC Cancer       Date:  2014-11-18       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.